La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bora Pharmaceuticals Croissance future

Future contrôle des critères 6/6

Bora Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 21.4% et de 26.6% par an respectivement. Le BPA devrait croître de de 21.2% par an. Le rendement des capitaux propres devrait être 29% dans 3 ans.

Informations clés

30.1%

Taux de croissance des bénéfices

29.9%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	17.2%
Taux de croissance des recettes	27.2%
Rendement futur des capitaux propres	28.2%
Couverture par les analystes	Good
Dernière mise à jour	05 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Jul 18

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Jun 13

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Apr 10

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Apr 08

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Mar 14

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Apr 30

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Mar 17

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Feb 17

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Jan 27

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Jan 19

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Dec 29

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Dec 09

Prévisions de croissance des bénéfices et des revenus

TWSE:6472 - Estimations futures des analystes et données financières antérieures (TWD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	29,123	N/A	N/A	N/A	1
12/31/2025	23,222	4,947	5,337	6,157	6
12/31/2024	18,693	3,669	2,933	3,952	5
6/30/2024	14,166	3,187	-575	1,011	N/A
3/31/2024	12,277	2,707	2,306	3,871	N/A
12/31/2023	14,200	3,030	3,183	4,614	N/A
9/30/2023	16,293	2,868	2,848	4,257	N/A
6/30/2023	15,942	2,704	4,038	4,362	N/A
3/31/2023	14,158	2,252	3,684	3,926	N/A
12/31/2022	10,494	1,392	1,810	2,010	N/A
9/30/2022	6,346	1,128	1,322	1,465	N/A
6/30/2022	4,811	697	844	1,029	N/A
3/31/2022	4,650	594	1,079	1,389	N/A
12/31/2021	4,900	750	873	1,237	N/A
9/30/2021	4,418	1,045	636	975	N/A
6/30/2021	3,626	963	286	603	N/A
3/31/2021	2,794	868	-261	-43	N/A
12/31/2020	1,800	578	26	178	N/A
9/30/2020	1,523	191	-608	188	N/A
6/30/2020	1,513	232	-317	415	N/A
3/31/2020	1,521	262	-211	478	N/A
12/31/2019	1,529	305	-467	232	N/A
9/30/2019	1,517	355	373	449	N/A
6/30/2019	1,492	283	305	373	N/A
3/31/2019	1,515	267	262	318	N/A
12/31/2018	1,372	443	130	167	N/A
9/30/2018	1,107	351	-56	-40	N/A
6/30/2018	846	330	-228	-218	N/A
3/31/2018	525	274	N/A	-263	N/A
12/31/2017	358	14	N/A	20	N/A
9/30/2017	323	17	N/A	2	N/A
6/30/2017	297	22	N/A	22	N/A
3/31/2017	291	24	N/A	5	N/A
12/31/2016	283	25	N/A	-18	N/A
9/30/2016	273	23	N/A	-20	N/A
6/30/2016	260	18	N/A	-22	N/A
3/31/2016	247	26	N/A	-4	N/A
12/31/2015	238	34	N/A	9	N/A
9/30/2015	236	30	N/A	18	N/A
6/30/2015	234	28	N/A	13	N/A
3/31/2015	226	23	N/A	16	N/A
12/31/2014	218	17	N/A	18	N/A
9/30/2014	182	16	N/A	8	N/A
6/30/2014	154	16	N/A	0	N/A
3/31/2014	123	10	N/A	-11	N/A
12/31/2013	93	4	N/A	-21	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 6472 ( 21.4% par an) est supérieure au taux d'épargne ( 1% ).

Bénéfices vs marché: Les bénéfices de 6472 ( 21.4% par an) devraient croître plus rapidement que le marché TW ( 18.7% par an).

Croissance élevée des bénéfices: Les bénéfices de 6472 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 6472 ( 26.6% par an) devrait croître plus rapidement que le marché TW ( 11.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 6472 ( 26.6% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 6472 devrait être élevé dans 3 ans ( 29 %)

Bora Pharmaceuticals Croissance future

Future contrôle des critères 6/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.0% to NT$935

Consensus revenue estimates increase by 11%

Price target increased by 17% to NT$827

Price target increased by 7.7% to NT$713

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 32%

Recent updates

Tanvex BioPharma, Inc. (TWSE:6541) agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. (TWSE:6472) and others for TWD 4.52 billion.

New major risk - Financial position

Price target increased by 8.0% to NT$935

Bora Pharmaceuticals Co., LTD. to Report Q2, 2024 Results on Aug 13, 2024

New minor risk - Share price stability

Upcoming dividend of NT$12.00 per share

Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Investor sentiment improves as stock rises 15%

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

First quarter 2024 earnings: EPS exceeds analyst expectations

Bora Pharmaceuticals Co., LTD. to Report Q1, 2024 Results on May 14, 2024

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Investor sentiment improves as stock rises 18%

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Consensus revenue estimates increase by 11%

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Bora Pharmaceuticals Co., LTD., Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS misses analyst expectations

Price target increased by 17% to NT$827

Price target increased by 7.7% to NT$713

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 11%

SunWay Biotech Co., LTD. (TPEX:1271) agreed to acquire Bora Health Inc from Bora Pharmaceuticals Co., LTD. (TPEX:6472).

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 15%

Upcoming dividend of NT$8.00 per share at 1.0% yield

Bora Pharmaceuticals Co., Ltd. Elects Lin Hsin-I as Independent Director

Bora Pharmaceuticals Co., LTD. to Report Q1, 2023 Results on May 17, 2023

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates increase by 18%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 31%

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Price target increased to NT$231

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.50 per share

Bora Pharmaceuticals Co., LTD. Announces Common Stock Cash Dividend, Payable on August 2, 2022

Bora Pharmaceuticals Co., LTD. announced that it has received TWD 800 million in funding

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target increased to NT$302

Third quarter 2021 earnings released: EPS NT$2.02 (vs NT$0.82 in 3Q 2020)

Price target increased to NT$276

Investor sentiment deteriorated over the past week

Upcoming dividend of NT$2.00 per share

Second quarter 2021 earnings released: EPS NT$2.54 (vs NT$0.80 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$6.18 (vs NT$0.84 in 1Q 2020)

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Investor sentiment improved over the past week

Consensus revenue estimates increase to NT$5.23b

Price target increased to NT$219

Full year 2020 earnings released: EPS NT$10.76 (vs NT$6.08 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Investor sentiment improved over the past week